The economic impact of intermittent high-dose intravenous versus oral corticosteroid treatment of juvenile dermatomyositis

Marisa S. Klein-Gitelman*, Teresa Waters, Lauren M. Pachman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

Objective. To perform a cost-identification and cost-effectiveness analysis comparing oral corticosteroids (OCS) with high-dose intermittent intravenous corticosteroid (IVCS) regimens in the treatment of juvenile dermatomyositis (JDM). Methods. Children previously diagnosed and treated for JDM (without myositis-specific or myositis-associated autoantibodies) at a single medical center by a single provider were identified. Two treatment protocols were compared: OCS and IVCS. Data on initial disease severity, time to remission, resource use, and costs generated were collected from patient records. Incremental cost-effectiveness ratios (ICE) were constructed. Results. Patients treated with IVCS achieved median remission 2 years earlier at median increased cost of $13,736. The ICE ratio comparing IVCS to OCS is $6,868 per year of disease avoided. Conclusion. This study suggests that, although IVCS treatments are costly, they are cost-effective.

Original languageEnglish (US)
Pages (from-to)360-368
Number of pages9
JournalArthritis Care and Research
Volume13
Issue number6
DOIs
StatePublished - 2000

Keywords

  • Cost identification
  • Cost-effectiveness
  • High-dose intravenous corticosteroids
  • Juvenile dermatomyositis

ASJC Scopus subject areas

  • Rheumatology

Fingerprint Dive into the research topics of 'The economic impact of intermittent high-dose intravenous versus oral corticosteroid treatment of juvenile dermatomyositis'. Together they form a unique fingerprint.

Cite this